# US 2006/0052322 A1 · Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0052322 A1
- Document ID: US20060052322A1
- Status: Published application
- Kind: A1
- Application number: 11/150,521
- Filed: 2005-06-10
- Published: 2006-03-09
- Earliest claimed: 2004-06-11
- Assignees: Introgen Therapeutics, Inc.
- Inventors: Jack Roth; Guido Schumacher; Sunil Chada
- Web page: https://patentgrep.com/patent/US20060052322A1

## CPC

- C12N 15/86: Viral vectors
- A61K 38/1709: {from mammals}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention concerns cancer therapy employing an expression construct that affects regulation of one or more particular nucleic acid sequences that encodes a gene product to which an agent is then targeted. In specific embodiments, the present invention relates to the use of p53 gene therapy to treat cancers in combination with Erbitux™(cetuximab). Viral and non-viral gene delivery systems are disclosed.

## Claims

### Claim 1

A method of treating a subject with cancer comprising administering to said subject:
(a) a p53 expression construct comprising a nucleic acid segment encoding p53, said segment under the control of a promoter active in a cancer cell of said subject, said p53 expression construct expressing p53 in said cancer cell; and
(b) an agent that targets the expressed product of a p53 expression construct-responsive nucleic acid sequence in said cell, whereby said expression construct and agent are provided in amounts that treat said cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the expression construct and the agent are administered concomitantly or in succession.

### Claim 3 (depends on 1)

The method of claim 1, wherein the expression construct is administered prior to the agent.

### Claim 4 (depends on 1)

The method of claim 1, wherein the agent is further defined as targeting the expressed product of a p53 expression construct-responsive nucleic acid sequence or a downstream nucleic acid sequence therefrom.

### Claim 5 (depends on 1)

The method of claim 1, wherein the p53-responsive nucleic acid sequence is upregulated in response to the p53 expression construct.

### Claim 6 (depends on 1)

The method of claim 1, wherein the p53-responsive nucleic acid sequence is downregulated in response to the p53 expression construct.

### Claim 7 (depends on 1)

The method of claim 1, wherein the p53-responsive nucleic acid sequence encodes a growth factor receptor, a receptor tyrosine kinase, a cell surface receptor, or a combination thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the p53-responsive nucleic acid sequence is epidermal growth factor receptor (EGFR), cox-2, Bax, IGFBP3, IGFBP4, Mdm2, MMP-2, TGF-alpha, IL-8R, p21, caveolin, DR5, Jun-B, Gpc, HO1, Btk, Htk, Bax, PIG3, Mdm2, PET-3, PET-7, ATDC, B61, PET-1, PET-8, PET-4, Gadd45, RTP, IGBP3, ET2, Mat8, PET-9, Fas, PET-11, 14-3-3σ, endothelin 2, negative growth regulator MyD118, TRAIL receptor 2 (KILLER/DR5), TGF-beta superfamily protein, caveolin, collagen, type II alpha1, nuclear matrix protein NRP/B(NRPB), p53, GADD45, regulator of G-protein signaling 2 G0S8, potassium channel alpha subunit, tyrosine protein kinase receptor eck, Pig3, actin alpha 2, APO-1/FAS, cystathionin-beta-synthase, macrophage stimulating protein (msp), complement component 4A, tetraspan NET-1, keratin 5, plasminogen activator inhibitor PAI-1, Ral GDP dissociation stimulator, collagen type VI alpha 1, TGF-alpha, endogenous retrovirus H and E sequence, keratin 17, EST similar to KIAA0835 protein, keratin 19, rhoHP 1, serum amyloid a protein precursor, interferon-induced 17-kD protein, interleukin-2 receptor beta chain (IL-2Rb), annexin-XIII, semaphorin V, neutrophil NADPH oxidase 2, estradiol 17 beta dehydrogenase 1, BMP4, P protein (melanocyte-specific transporter), thrombospondin 1, human activated p21cdc42Hs kinase (ack), P2XM, Pig12, phosphoglyverate mutase I, possible GTP-binding protein hsr1, superoxide dismutase 3 (extracellular), cyclin-dependent kinase 2, retinoblastoma-binding protein, DNA replication licensing factor cdc47 homolog, prothymosin alpha, EST similar to cyclin B2, ADP-ribosylation factor-like protein 2 (ARL2), human non-histone chromosomal protein HMG-17, mitotic feedback control protein Madp2 homology, KIAA0101 gene, HMG2, KIAA0030, prostatic binding protein, ATPase Na+/K+ transporting beta 1 polypeptide, lamin B receptor, DNA primase polypeptide 1, topoisomerase (DNA) II alpha, Myb proto-oncogene protein, human effector cell protease receptor-1 (EPR-1), CCAAT/enhancer binding protein C/EPBalpha, ribosomal protein S6 kinase 90 kD polypeptide 2, and InsP3 5 phosphatase, component C1 inhibitor, catechol o-methyltransferase, L-histidine decarboxylase, carboxyl ester lipase, interleukin 8 receptor-alpha, alpha-fetoprotein, alpha 1-acid glyprotein 2, cardiotrophin, IGFBP4, JunB, myoglobin, or MDR1.

### Claim 9 (depends on 1)

The method of claim 1, wherein the agent is a small molecule or an antibody.

### Claim 10 (depends on 9)

The method of claim 9, wherein the antibody is a monoclonal antibody.

### Claim 11 (depends on 1)

The method of claim 1, wherein the p53-responsive nucleic acid sequence is EGFR and the agent is cetuximab, gefitinib, or erlotinib.

### Claim 12 (depends on 1)

The method of claim 1, wherein said expression construct is a viral expression construct.

### Claim 13 (depends on 12)

The method of claim 12, wherein said viral expression construct is a retroviral construct, a herpesviral construct, an adenoviral construct, an adeno-associated viral construct, or a vaccinia viral construct.

### Claim 14 (depends on 12)

The method of claim 12, wherein said viral expression construct is a replication-competent virus.

### Claim 15 (depends on 12)

The method of claim 12, wherein said viral expression construct is a replication-defective virus.

### Claim 16 (depends on 1)

The method of claim 1, wherein said expression construct is a non-viral expression construct.

### Claim 17 (depends on 16)

The method of claim 16, wherein said non-viral expression construct is comprised within a lipid vehicle.

### Claim 18 (depends on 1)

The method of claim 1, wherein said promoter is selected from CMV IE, RSV LTR, β-actin, Ad-E1, Ad-E2 or Ad-MLP.

### Claim 19 (depends on 1)

The method of claim 1, further defined as indirectly or directly producing apoptosis in said cancer cell.

### Claim 20 (depends on 1)

The method of claim 1, further defined as conferring chemosensitivity to said cancer cell.

### Claim 21

A method of treating a subject with cancer comprising administering to said subject, in combination,
(a) an expression construct comprising a nucleic acid segment encoding p53, said segment under the control of a promoter active in a cancer cell of said subject, said expression construct expressing p53 in said cancer cell; and
(b) cetuximab,
whereby said expression construct and cetuximab are provided in amounts that treat said cancer.

### Claim 22 (depends on 21)

The method of claim 21, wherein said cancer is selected from the group consisting of brain cancer, head & neck cancer, esophageal cancer, tracheal cancer, lung cancer, liver cancer stomach cancer, colon cancer, pancreatic cancer, breast cancer, cervical cancer, uterine cancer, bladder cancer, prostate cancer, testicular cancer, skin cancer, rectal cancer lymphoma and leukemia.

### Claim 23 (depends on 21)

The method of claim 21, wherein the cancer is metastatic.

### Claim 24 (depends on 21)

The method of claim 21, wherein cancer is recurrent.

### Claim 25 (depends on 24)

The method of claim 24, wherein recurrence is recurrence at a primary tumor site.

### Claim 26 (depends on 24)

The method of claim 24, wherein recurrence is recurrence at a metastatic site.

### Claim 27 (depends on 21)

The method of claim 21, wherein said subject has had surgical resection prior to administration (a).

### Claim 28 (depends on 21)

The method of claim 21, further comprising surgical resection following administration (b).

### Claim 29 (depends on 21)

The method of claim 21, wherein administration (a) is selected from the group consisting of intratumoral, to a tumor vasculature, local to a tumor, regional to a tumor, and systemic.

### Claim 30 (depends on 21)

The method of claim 21, wherein administration (b) is selected from the group consisting of intratumoral, to a tumor vasculature, local to a tumor, regional to a tumor, and systemic.

### Claim 31 (depends on 21)

The method of claim 21, wherein the subject is a human subject.

### Claim 32 (depends on 21)

The method of claim 21, further comprising an additional distinct cancer therapy.

### Claim 33 (depends on 32)

The method of claim 32, wherein the additional distinct cancer therapy is chemotherapy, radiotherapy, non-p53 gene therapy, non-Erbitux™ immunotherapy, hormonal therapy, or toxin therapy.

### Claim 34

A pharmaceutical formulation comprising (a) an expression construct comprising a nucleic acid segment encoding p53, said segment under the control of a promoter active in a cancer cell of said subject; and (b) an agent that targets a gene product of the nucleic acid segment.

### Claim 35

A kit comprising, in separate containers, (a) an expression construct comprising a nucleic acid segment encoding p53, said segment under the control of a promoter active in a cancer cell of said subject; and (b) an agent that targets a gene product of the nucleic acid segment.
